CNAP Artemisia Project

    HOME        ABOUT US         RESEARCH        INTO PRACTICE       LINKS    
 
Aims of the project BenefitsFAQ bullet graphic   Fact sheets   Artemisia annua L. Artemisinin bullet graphic   ACTsStaff
ACT tablets: the most effective malaria treatments

Artemisinin combination therapies

Quick Facts:

  • Artemisinin should be used with a partner drug as Artemisinin Combination Therapies (ACTs)
  • ACTs are the most effective treatments for malaria
  • Annual demand for treatments has increased dramatically to around 229 million
  • ACTs are expensive compared to the medicines they are replacing and this is a barrier to access
  • In 2010, 181 million courses of ACT were procured worldwide in the public sector

The need for combination therapies

Artemisinin and its derivatives should be taken in conjunction with a partner drug as an Artemisinin Combination Therapy (ACT). There are two reasons for this. Firstly, artemisinin drugs do not last long in the human body. Because of this, partnering them with another drug that persists for longer improves treatment efficacy and reduces the duration of the treatment course that is required. Secondly, combining two drugs with different modes of action impedes the development of parasite resistance to either constituent: artemisinins are a vital part of our defences against malaria and so it is essential that their effectiveness is protected with combination therapies.

The first ACT to become available internationally was Coartem™, a combination of artemether and lumefantrine, produced by Novartis. Its introduction to the KwaZulu Natal province of South Africa in 2000 contributed to a dramatic reduction in malaria transmission in conjunction with other measures such as insecticidal spraying and treated bed nets. A full treatment is a three-day course and the number of tablets per dose depends on body weight. It is taken orally with fluids (preferably drinks containing fat, such as milk). There are five ACTs currently recommended for use; the choice of ACT is based on the efficacy of the combination in the country and area of intended use.

Demand for artemisinin and ACTs

The WHO has identified ACTs as the most effective treatments currently available for malaria. As a result, many malaria endemic countries have adopted them as their drugs of choice. From 2001-2006 demand for artemisinin rocketed from a few hundred thousand courses to around 80 million. In 2008 the Global Malaria Action Plan was published. This plan involved a major scaling up in the use of ACT malaria treatments. By 2010 annual demand had further risen to an estimated 229 million treatments. This level of usage requires around 115 tonnes of artemisinin.

ACT prices

A course of ACT costs between US$ 0.9 – 1.40 for an adult and US$ 0.30 – 0.40 for a young child.  This compares with a typical price of 10 -15 cents for treatment with chloroquine. Lower ACT prices are essential to making these drugs accessible in countries where the annual health budget may be less than a few dollars per capita. The high production costs of artemisinin contribute to problems with expense and availability. Artemisinin production is expensive because of the low yield from Artemisia plants. High food prices make Artemisia an uneconomic choice for farmers. Planting areas are down and there is a fear of shortages. In the past, such shortages have led to price hikes.

Poor quality and counterfeit drugs

Effective malaria treatment is also threatened by poor quality drugs with incorrect composition or ingredients. This may be due to negligence, error, insufficient resources or counterfeiting. The number and sophistication of fake drugs on the market is increasing and the relatively high market value of ACTs makes them a prime target for counterfeiters. In some areas of Africa, up to 80 percent of the artemisinin drugs sold on the private market have been found to be counterfeited. The WHO estimates that poor quality or incorrectly used malaria drugs are responsible for 200,000 deaths every year.

 back to top 


  
cnetre for novel agricultural products - CNAP department of biology - unversity of york
Department of Biology